Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel

Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerding, Heinrich, Monés, Jordi, Tadayoni, Ramin, Boscia, Francesco, Pearce, Ian, Priglinger, Siegfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345884/
https://www.ncbi.nlm.nih.gov/pubmed/25075121
http://dx.doi.org/10.1136/bjophthalmol-2014-305041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345884/
https://www.ncbi.nlm.nih.gov/pubmed/25075121
http://dx.doi.org/10.1136/bjophthalmol-2014-305041

Ejemplares similares